Omar Nadeem
Clinical Director, Myeloma Immune Effector Cell Therapy Program · Mass General Brigham
Credentials: · · · · ·
History
- Present
Myeloma Immune Effector Cell Therapy Program · Mass General Brigham
- Present
Center for Early Detection and Interception of Blood Cancers · Mass General Brigham
- Present
2009–2012Dartmouth-Hitchcock Medical Center
- 2005–2009
Research
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
New England Journal of Medicine · 2022 · 422 citations
Blood · 2025 · 135 citations
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Journal of Clinical Oncology · 2021 · 125 citations
29 papers
24 papers
24 papers
23 papers · 1 as a fellow
- AS
19 papers
19 papers
16 papers
15 papers
Clinical trials
- 2024–2034
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Principal investigator · Recruiting · Phase 1, Phase 2
Omar Nadeem, MD
- 2021–2027
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
- 2021–2030
- 2019–2027
Ixazomib + Pomalidomide + Dexamethasone In MM
Principal investigator · Active not recruiting · Phase 1, Phase 2
Omar Nadeem, MD